Advanced Pharmacotherapy Evidenced by Pathogenesis of Autism Spectrum Disorder.
- Author:
Yeon Jung LEE
1
;
Soo Hyun OH
;
Chanmin PARK
;
Minha HONG
;
Ah Rah LEE
;
Hee Jeong YOO
;
Chan Young SHIN
;
Keun Ah CHEON
;
Geon Ho BAHN
Author Information
1. Department of Psychiatry, Kyung Hee University School of Medicine, Seoul, Korea. mompeian@khu.ac.kr
- Publication Type:Review
- Keywords:
Child development disorders, pervasive;
Drug therapy;
Etiology
- MeSH:
Acetylcholine;
Behavioral Symptoms;
Chelating Agents;
Child;
Autism Spectrum Disorder*;
Complementary Therapies;
Diagnostic and Statistical Manual of Mental Disorders;
Drug Therapy*;
Glutamic Acid;
Oxytocin;
Pharmacogenetics;
Secretin;
Vitamins
- From:Clinical Psychopharmacology and Neuroscience
2014;12(1):19-30
- CountryRepublic of Korea
- Language:English
-
Abstract:
In clinical practice, pharmacological treatment is mostly focused on behavioral symptoms in everyday life. Nevertheless, persistent effort continues to develop medication for causal treatment. Recent changes in diagnostic criteria from Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) to DSM-5 would affect not only diagnosing approaches, but also therapeutic approaches. Because previous pervasive developmental disorders have been integrated into a single entity, the autism spectrum disorder (ASD), we have to prepare for what medications are valuable for the ASD. In this article, we reviewed the following etiological treatment: acetylcholine and glutamate related medicine; amino acid medicine such as secretin, endogenous opioid, and oxytocin; complementary and alternative medicine such as chelating agents, vitamins, and omega-3; promising drugs related to the scope of pharmacogenetics currently under study.
